Sign Out
There are no adequate data from the use of FEIBA in pregnant or lactating women. Physicians should balance the potential risks and only prescribe FEIBA if clearly needed, taking into consideration that pregnancy and the postpartum period confer an increased risk of thromboembolic events, and several complications of pregnancy that are associated with an increased risk of DIC.
No animal reproduction studies have been conducted with FEIBA, and the effects of FEIBA on fertility have not been established in controlled clinical trials.
See Precautions for information on parvovirus B19 infection.
